Revolution Medici…
USUSDRevolution Medicines, Inc. (US:RVMD) — Biotechnology: Biological Products (No Diagnostic Substances). A tőzsdék száma, ahol a vállalat részvényeivel kereskednek: 1. Ezen az oldalon — ár és grafikon, osztalékok, legnagyobb részvénytulajdonosok és a részvények számának alakulása.
A Cégről
- Weboldal
- revmed.com
- Befektetői Kapcsolatok
- revmed.com/investors/
- Szektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Székhely
- REDWOOD CITY, United States
- Vezérigazgató
- Mark A. Goldsmith
- Alkalmazottak
- 883
- Alapítva
- 2014
- Forgalomban Lévő Részvények
- 214.34 M 2026-07-31 állapot
- Közkézhányad
- 184.5 M
- Piaci Kapitalizáció
- 43.24 Mrd USD
- Bennfentesek
- 1.85%
- Intézményi Befektetők
- 101.01%
- Iparág (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- US76155X1000
- LEI
- 549300JU3X0LBCQ65892
- P/E
- veszteség
- FCF
- −1.23 Mrd USD
- Adósság
- ?
- Eredmények és FCF — a 30.06.2026-ig tartott 12 hónapra (a cég legfrissebb jelentése).
- NAV
Leírás
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Tőzsdék és Tickerek
| Tőzsde | Ticker | Pénznem | Ár | Típus |
|---|---|---|---|---|
| US USA Stocks | RVMD | USD | 189.26 -2.20% | közönséges részvény |
Legnagyobb Tulajdonosok
| Tulajdonos | Részesedés | Részvények | Jelentés Dátuma |
|---|---|---|---|
| Blackrock Inc. | 6.39% | 13.7 M | 2026-06-30 |
| Farallon Capital Managem… | 6.32% | 13.55 M | 2026-06-30 |
| FMR, LLC | 5.69% | 12.2 M | 2026-06-30 |
| Baker Bros. Advisors, LP | 5.34% | 11.44 M | 2026-06-30 |
| Jupiter Topco LLC | 5.01% | 10.74 M | 2026-06-30 |
| Darwin Global Management… | 4.96% | 10.63 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.24% | 9.09 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 3.87% | 8.29 M | 2026-06-30 |
| Nextech Invest, Ltd. | 3.55% | 7.6 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.99% | 6.41 M | 2026-06-30 |
| Paradigm Biocapital Advi… | 2.97% | 6.36 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.16% | 4.63 M | 2026-06-30 |
| Growth Fund of America | 1.38% | 2.96 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 2.67 M | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.15% | 2.47 M | 2026-07-31 |
| BORISY ALEXIS (Director) | ≈1.09% | 2.34 M | 2026-06-18 |
| VANGUARD INDEX FUNDS-Van… | 1.07% | 2.29 M | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.86% | 1.84 M | 2026-04-30 |
| iShares Trust-iShares Bi… | 0.65% | 1.39 M | 2026-07-31 |
| JPMorgan Trust II-JPMorg… | 0.54% | 1.17 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.51% | 1.1 M | 2026-07-31 |
| GOLDSMITH MARK A (Chief… | ≈0.46% | 984 238 | 2026-08-21 |
| KELSEY STEPHEN MICHAEL (… | ≈0.14% | 291 876 | 2026-09-11 |
| HORN MARGARET A (Chief O… | ≈0.07% | 154 647 | 2026-06-17 |
| ANDERS JACK LEE (Chief F… | ≈0.06% | 123 269 | 2026-06-24 |
| WANG XIAOLIN (Officer) | ≈0.05% | 116 063 | 2026-03-17 |
| LIN WEI (Officer) | ≈0.05% | 101 366 | 2026-03-17 |
| HORNING SANDRA (Director… | ≈0.05% | 97 765 | 2026-06-18 |
| CISLINI JEFFREY TODD (Ge… | ≈0.03% | 55 907 | 2026-08-21 |
| SCHROEDER THILO (Directo… | — | — | 2024-12-05 |
Bejelentkezés Google-Fiókkal